Myobloc (rimabotulinumtoxinB)

Myobloc (rimabotulinumtoxinB) is covered only for FDA‑approved adult indications—cervical dystonia (2,500–5,000 units total divided among affected muscles) and chronic sialorrhea (1,500–3,500 units divided among parotid and submandibular glands); non‑FDA uses are excluded. Key requirements: patient must be ≥18 years, approval is for 12 months, dosing must follow the specified ranges, injections no more frequently than every 12 weeks, and documentation of diagnosis and age is required.

"Approval duration: 12 months."

Sign up to see full coverage criteria, indications, and limitations.